Managers / Q1 2023 · view latest →
Sivik Global Healthcare LLC
CIK 0001596452 · 133 TACONIC RD, GREENWICH, CT, 06831 · 203-769-8600
Reported Value
$233M
Q1 2023
Positions
40
Filings on Record
30
2019–present window
Filed
May 8, 2023
original filing
Summary
Sivik Global Healthcare LLC reported $233M in U.S.-listed holdings across 40 positions for Q1 2023.
Its largest position, XBI, represents 6.6% of the portfolio.
Compared with Q4 2022, the fund opened 6 new positions and exited 5.
Portfolio Metrics
Turnover
+12.6%
vs prior filed quarter
Top-10 Concentration
+39.5%
share of reported value
Largest Position
+6.6%
Spdr S P Biotech Etf
New / Exited
6 / 5
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 89.3% · $208M
- ETP · 6.6% · $15M
- ADR · 4.1% · $10M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| MRKMerck & Co Inc | NEW | +75.0K | 75.0K | +$8M | $8M |
| ABBVAbbVie Inc | NEW | +40.0K | 40.0K | +$6M | $6M |
| MDTMedtronic PLC | NEW | +67.5K | 67.5K | +$5M | $5M |
| BDXBecton Dickinson & Co | NEW | +15.0K | 15.0K | +$4M | $4M |
| SRPTSarepta Therapeutics Inc | NEW | +13.0K | 13.0K | +$2M | $2M |
| ALNYAlnylam Pharmaceuticals Inc | NEW | +7.5K | 7.5K | +$2M | $2M |
| UNHUnitedHealth Group Inc | ADDED | +9.5K | 17.5K | +$4M | $8M |
| RVTYPerkinElmer Inc | SOLD OUT | −20.0K | 0 | −$3M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2023
40 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | XBISPDR S&P Biotech ETFhistory → | Cash Securities | 6.55% | $15M | 200.0K |
| 2 | HUMHumana Inchistory → | Cash Securities | 4.70% | $11M | 22.5K |
| 3 | NVONovo Nordisk A/Shistory → | Cash Securities | 4.10% | $10M | 60.0K |
| 4 | THCTenet Healthcare Corphistory → | Cash Securities | 3.83% | $9M | 150.0K |
| 5 | UNHUnitedHealth Group Inchistory → | Cash Securities | 3.56% | $8M | 17.5K |
| 6 | MRKMerck & Co Inchistory → | Cash Securities | 3.43% | $8M | 75.0K |
| 7 | HCAHCA Healthcare Inchistory → | Cash Securities | 3.40% | $8M | 30.0K |
| 8 | BSXBoston Scientific Corphistory → | Cash Securities | 3.33% | $8M | 155.0K |
| 9 | ZBHZimmer Biomet Holdings Inchistory → | Cash Securities | 3.33% | $8M | 60.0K |
| 10 | ISRGIntuitive Surgical Inchistory → | Cash Securities | 3.29% | $8M | 30.0K |
| 11 | SYKStryker Corphistory → | Cash Securities | 3.07% | $7M | 25.0K |
| 12 | UHSUniversal Health Services Inchistory → | Cash Securities | 3.00% | $7M | 55.0K |
| 13 | LLYEli Lilly & Cohistory → | Cash Securities | 2.95% | $7M | 20.0K |
| 14 | CORAmerisourceBergen Corphistory → | Cash Securities | 2.75% | $6M | 40.0K |
| 15 | ABBVAbbVie Inchistory → | Cash Securities | 2.74% | $6M | 40.0K |
| 16 | TMOThermo Fisher Scientific Inchistory → | Cash Securities | 2.73% | $6M | 11.0K |
| 17 | BAXBaxter International Inchistory → | Cash Securities | 2.62% | $6M | 150.0K |
| 18 | CAHCardinal Health Inchistory → | Cash Securities | 2.60% | $6M | 80.0K |
| 19 | SGRYSurgery Partners Inchistory → | Cash Securities | 2.59% | $6M | 175.0K |
| 20 | AAgilent Technologies Inchistory → | Cash Securities | 2.38% | $6M | 40.0K |
| 21 | MDTMedtronic PLChistory → | Cash Securities | 2.34% | $5M | 67.5K |
| 22 | MCKMcKesson Corphistory → | Cash Securities | 2.30% | $5M | 15.0K |
| 23 | ACHCAcadia Healthcare Co Inchistory → | Cash Securities | 2.17% | $5M | 70.0K |
| 24 | DHRDanaher Corphistory → | Cash Securities | 2.17% | $5M | 20.0K |
| 25 | BMRNBioMarin Pharmaceutical Inchistory → | Cash Securities | 2.09% | $5M | 50.0K |
| 26 | ELVElevance Health Inchistory → | Cash Securities | 2.08% | $5M | 10.5K |
| 27 | VRTXVertex Pharmaceuticals Inchistory → | Cash Securities | 2.03% | $5M | 15.0K |
| 28 | WATWaters Corphistory → | Cash Securities | 2.00% | $5M | 15.0K |
| 29 | ABTAbbott Laboratorieshistory → | Cash Securities | 1.96% | $5M | 45.0K |
| 30 | IQVIQVIA Holdings Inchistory → | Cash Securities | 1.71% | $4M | 20.0K |
| 31 | CICigna Group/Thehistory → | Cash Securities | 1.65% | $4M | 15.0K |
| 32 | BDXBecton Dickinson & Cohistory → | Cash Securities | 1.60% | $4M | 15.0K |
| 33 | Seagen Inc | Cash Securities | 1.39% | $3M | 16.0K |
| 34 | ICLRICON PLChistory → | Cash Securities | 1.38% | $3M | 15.0K |
| 35 | EHCEncompass Health Corphistory → | Cash Securities | 1.28% | $3M | 55.0K |
| 36 | S24Select Medical Holdings Corphistory → | Cash Securities | 1.20% | $3M | 107.8K |
| 37 | BIIBBiogen Inchistory → | Cash Securities | 1.20% | $3M | 10.0K |
| 38 | OPCHOption Care Health Inchistory → | Cash Securities | 1.09% | $3M | 80.0K |
| 39 | SRPTSarepta Therapeutics Inc | Cash Securities | 0.77% | $2M | 13.0K |
| 40 | ALNYAlnylam Pharmaceuticals Inc | Cash Securities | 0.65% | $2M | 7.5K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $132M | 34 | Apr 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $345M | 49 | Jan 21, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $344M | 44 | Oct 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $368M | 46 | Jul 25, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $185M | 31 | Apr 22, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $190M | 38 | Jan 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $236M | 35 | Nov 6, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $278M | 38 | Jul 29, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $427M | 47 | May 1, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $239M | 39 | Feb 5, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $198M | 33 | Nov 7, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $428M | 43 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $233M | 40 | May 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $213M | 39 | Feb 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $180M | 41 | Nov 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $176M | 38 | Aug 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $242M | 49 | May 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $233M | 45 | Feb 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $419M | 43 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $512M | 49 | Aug 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $274M | 47 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $245M | 38 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $232M | 38 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $302M | 52 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $253M | 40 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $269M | 50 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $198M | 45 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $414M | 62 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $271M | 61 | May 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $186M | 48 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.